Home » Medical Devices » Non-Hormonal Alternatives for Menopause Market

Non-Hormonal Alternatives for Menopause Market by Indication (Hot Flashes, Vaginal Dryness, Others (Chills, Night Sweats, Sleep Problems, Mood Changes, etc.)) by Therapy (Selective serotonin reuptake inhibitors (SSRIs), Selective serotonin-norepinephrine reuptake inhibitors (SNRIs), Plant-derived estrogens (phytoestrogens), Herbal treatments, Over-the-counter therapies, Others) by Application – Ukraine War, Future Prospects And Competitive Analysis, 2016 – 2028

Published: | Report ID: 14331 | Report Format : PDF

Market Insights

With the ever-increasing population of women reaching menopause worldwide, the demand for Non-Hormonal Alternatives for Menopause is proliferating and has bagged the revenue of USD 7,929 million in 2021. Moreover, the need for Non-Hormonal Alternatives for Menopause is likely to exhibit a rapid CAGR of over 7.5% over the forecast period to reach the valuation of USD 13,465 million in 2028. Meanwhile, the cumulative revenue growth opportunity offered by the global Non-Hormonal Alternatives for Menopause market is expected to reach over USD 76.5 billion between 2022 and 2028.

Non-Hormonal Alternatives for Menopause Market

Interesting Facts about Non-Hormonal Alternatives for Menopause Industry

  • More than 2 million women reach menopause in the U.S. alone, and over 40 million worldwide
  • Over 60 to 70 percent of women reaching menopause face problems such as hot flashes
  • Antidepressants are most widely used to treat hot flashes
  • S. accounted for over 30% share of the revenue generated by the Non-Hormonal Alternatives for Menopause market
  • Europe is the second leading market for Non-Hormonal Alternatives for Menopause

Risk Associated with Hormonal Replacement Therapy to Drive the Demand for Non-Hormonal Alternatives for Menopause

Despite its efficiency, hormonal replacement therapy is not considered the first choice of treatment for menopause in women. The reason is hormonal replacement therapy has been considered a potential risk for the development of breast cancer in women. In addition, since a study published by the Women’s Health Initiative, physicians have become reluctant to prescribe hormone replacement therapy. Over two-thirds of women facing such problems are given Non-Hormonal Alternatives for Menopause symptoms.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Antidepressants to Trigger the Growth of Non-Hormonal Alternatives for Menopause    

Selective serotonin reuptake inhibitors (SSRIs), Selective serotonin-norepinephrine reuptake inhibitors (SNRIs), Plant-derived estrogens (phytoestrogens), Herbal treatments, Over-the-counter therapies, and Others are effective therapies used for the treatment of menopause. Non-hormonal treatments for vasomotor symptoms include selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs), which reduce HF severity and frequency by 20 to 65 percent. Since HFs are considered to be caused by alterations in thermoregulation caused by estrogen shortage, which leads to a drop in serotonin levels, the blockade of serotonin and norepinephrine receptors induced by SSRIs and SNRIs may help to counteract this imbalance. Although several studies have examined the efficacy of SSRIs and SNRIs in lowering HFs, paroxetine salt 7.5 mg/day is the only FDA-approved medicine for treating moderate-to-severe vasomotor symptoms in postmenopausal women.

Hot Flashes to Drive the Demand for Non-Hormonal Alternatives for Menopause

Hot Flashes, Vaginal Dryness, and Others (Chills, Night Sweats, Sleep Problems, Mood Changes, etc.0 are some of the significant indications that drive the demand for Non-Hormonal Alternatives for Menopause. Hot flashes are the most common of all menopause symptoms, affecting over 85% of women undergoing menopause symptoms. In contrast, vaginal dryness accounts for the second largest share of revenue generated by the Non-Hormonal Alternatives for Menopause market. Therefore, it is also expected to exhibit rapid growth over the forecast period.

The Asia Pacific to Witness Rapid Growth in Demand for Non-Hormonal Alternatives for Menopause

Strong growth in demand for Non-Hormonal Alternatives for Menopause in China, India, South Korea, and Japan is leading the development of the Asia Pacific market. The massive population of women in China and India and the large number of women reaching menopause every year, coupled with increasing health awareness and growing per capita expenditure on healthcare in the region, is another factor fueling the growth of Non-Hormonal Alternatives for Menopause. While the U.S. is the leading market for Non-Hormonal Alternatives for Menopause, with over 25% share in the global Non-Hormonal Alternatives for Menopause market. A high level of awareness, higher spending power, higher penetration of alternative therapies, etc., is mainly responsible for the strong growth of Non-Hormonal Alternatives for Menopause in the U.S. Similarly, Europe also holds a significant position in the global Non-Hormonal Alternatives for Menopause market.  Germany, UK and France are leading overall growth of European Non-Hormonal Alternatives for Menopause market.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Strong Product Pipeline and Focus on Innovation to Propel the Future Growth of Non-Hormonal Alternatives for Menopause 

Swor Women’s Care, Paladin Labs, Boehringer Ingelheim, Pfizer, Organon Inc., Lupin and GSK are some of the leading players in global Non-Hormonal Alternatives for Menopause market. There are large number of players operating in the global Non-Hormonal Alternatives for Menopause market. Key players have invested huge amount of sum on the development of new therapies for menopause. There is strong pipeline of Non-Hormonal Alternatives for Menopause. Banking on their strong R&D capabilities, companies are thriving to bring innovative alternatives to hormonal therapies with no compromise in their efficiency.

Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Segmentation

2. Executive Summary
2.1. Market Snapshot: Global Non-Hormonal Alternatives for Menopause Market

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Non-Hormonal Alternatives for Menopause Market Value, 2016-2028, (US$ Bn)
3.2. Market Dynamics
3.2.1. Key Growth Trends
3.2.2. Major Industry Challenges
3.2.3. Key Growth Pockets
3.3. Attractive Investment Proposition,2021
3.3.1. Indication
3.3.2. Therapy
3.3.3. End-user
3.3.4. Geography
3.4. Porter’s Five Forces Analysis
3.4.1. Threat of New Entrants
3.4.2. Bargaining Power of Buyers/Consumers
3.4.3. Bargaining Power of Suppliers
3.4.4. Threat of Substitute Indications
3.4.5. Intensity of Competitive Rivalry
3.5. Value Chain Analysis

4. Market Positioning of Key Players, 2021
4.1. Company market share of key players, 2021
4.2. Top 6 Players
4.3. Top 3 Players
4.4. Major Strategies Adopted by Key Players

5. COVID 19 Impact Analysis
5.1. Global Non-Hormonal Alternatives for Menopause Market Pre Vs Post COVID 19, 2019 – 2028
5.2. Impact on Import & Export
5.3. Impact on Demand & Supply

6. North America
6.1. North America Non-Hormonal Alternatives for Menopause Market, by Country, 2016-2028(US$ Bn)
6.1.1. U.S.
6.1.2. Canada
6.1.3. Mexico
6.2. North America Non-Hormonal Alternatives for Menopause Market, by Indication, 2016-2028(US$ Bn)
6.2.1. Overview
6.2.2. Health Women
6.2.3. Breast cancer survivors
6.3. North America Non-Hormonal Alternatives for Menopause Market, by End-user, 2016-2028(US$ Bn)
6.3.1. Overview
6.3.2. Selective serotonin-norepinephrine reuptake inhibitors (SNRIs)
6.3.3. Plant-derived estrogens (phytoestrogens) s
6.3.4. Selective serotonin reuptake inhibitors (SSRIs)
6.3.5. Herbal treatments
6.3.6. Over-the-counter therapies
6.3.7. Others
6.4. North America Non-Hormonal Alternatives for Menopause Market, by Therapy, 2016-2028(US$ Bn)
6.4.1. Overview
6.4.2. Hot Flashes
6.4.3. Vaginal Dryness
6.4.4. Others

7. Europe
7.1. Europe Non-Hormonal Alternatives for Menopause Market, by Country, 2016-2028(US$ Bn)
7.1.1. UK
7.1.2. France
7.1.3. Germany
7.1.4. Italy
7.1.5. Russia
7.1.6. Spain
7.1.7. Belgium
7.1.8. Netherland
7.1.9. Austria
7.1.10. Sweden
7.1.11. Poland
7.1.12. Denmark
7.1.13. Switzerland
7.1.14. Rest of Europe
7.2. Europe Non-Hormonal Alternatives for Menopause Market, by Indication, 2016-2028(US$ Bn)
7.2.1. Overview
7.2.2. Health Women
7.2.3. Breast cancer survivors
7.3. Europe Non-Hormonal Alternatives for Menopause Market, by End-user, 2016-2028(US$ Bn)
7.3.1. Overview
7.3.2. Selective serotonin-norepinephrine reuptake inhibitors (SNRIs)
7.3.3. Plant-derived estrogens (phytoestrogens) s
7.3.4. Selective serotonin reuptake inhibitors (SSRIs)
7.3.5. Herbal treatments
7.3.6. Over-the-counter therapies
7.3.7. Others
7.4. Europe Non-Hormonal Alternatives for Menopause Market, by Therapy, 2016-2028(US$ Bn)
7.4.1. Overview
7.4.2. Hot Flashes
7.4.3. Vaginal Dryness
7.4.4. Others

8. Asia Pacific
8.1. Asia Pacific Non-Hormonal Alternatives for Menopause Market, by Country, 2016-2028(US$ Bn)
8.1.1. China
8.1.2. Japan
8.1.3. South Korea
8.1.4. India
8.1.5. Australia
8.1.6. New Zealand
8.1.7. Taiwan
8.1.8. Southeast Asia
8.1.9. Central Asia
8.1.10. Rest of Asia Pacific
8.2. Asia Pacific Non-Hormonal Alternatives for Menopause Market, by Indication, 2016-2028(US$ Bn)
8.2.1. Overview
8.2.2. Health Women
8.2.3. Breast cancer survivors
8.3. Asia Pacific Non-Hormonal Alternatives for Menopause Market, by End-user, 2016-2028(US$ Bn)
8.3.1. Overview
8.3.2. Selective serotonin-norepinephrine reuptake inhibitors (SNRIs)
8.3.3. Plant-derived estrogens (phytoestrogens) s
8.3.4. Selective serotonin reuptake inhibitors (SSRIs)
8.3.5. Herbal treatments
8.3.6. Over-the-counter therapies
8.3.7. Others
8.4. Asia Pacific Non-Hormonal Alternatives for Menopause Market, by Therapy, 2016-2028(US$ Bn)
8.4.1. Overview
8.4.2. Hot Flashes
8.4.3. Vaginal Dryness
8.4.4. Others

9. Latin America
9.1. Latin America Non-Hormonal Alternatives for Menopause Market, by Country, 2016-2028(US$ Bn)
9.1.1. Brazil
9.1.2. Argentina
9.1.3. Peru
9.1.4. Chile
9.1.5. Colombia
9.1.6. Rest of Latin America
9.2. Latin America Non-Hormonal Alternatives for Menopause Market, by Indication, 2016-2028(US$ Bn)
9.2.1. Overview
9.2.1.1. Health Women
9.2.1.2. Breast cancer survivors
9.3. Latin America Non-Hormonal Alternatives for Menopause Market, by End-user, 2016-2028(US$ Bn)
9.3.1. Overview
9.3.2. Selective serotonin-norepinephrine reuptake inhibitors (SNRIs)
9.3.3. Plant-derived estrogens (phytoestrogens) s
9.3.4. Selective serotonin reuptake inhibitors (SSRIs)
9.3.5. Herbal treatments
9.3.6. Over-the-counter therapies
9.3.7. Others
9.4. Latin America Non-Hormonal Alternatives for Menopause Market, by Therapy, 2016-2028(US$ Bn)
9.4.1. Overview
9.4.2. Hot Flashes
9.4.3. Vaginal Dryness
9.4.4. Others

10. Middle East
10.1. Middle East Non-Hormonal Alternatives for Menopause Market, by Country, 2016-2028(US$ Bn)
10.1.1. UAE
10.1.2. KSA
10.1.3. Israel
10.1.4. Turkey
10.1.5. Iran
10.1.6. Rest of Middle East
10.2. Middle East Non-Hormonal Alternatives for Menopause Market, by Indication, 2016-2028(US$ Bn)
10.2.1. Overview
10.2.2. Health Women
10.2.3. Breast cancer survivors
10.3. Middle East Non-Hormonal Alternatives for Menopause Market, by End-user, 2016-2028(US$ Bn)
10.3.1. Overview
10.3.2. Selective serotonin-norepinephrine reuptake inhibitors (SNRIs)
10.3.3. Plant-derived estrogens (phytoestrogens) s
10.3.4. Selective serotonin reuptake inhibitors (SSRIs)
10.3.5. Herbal treatments
10.3.6. Over-the-counter therapies
10.3.7. Others
10.4. Middle East Non-Hormonal Alternatives for Menopause Market, by Therapy, 2016-2028(US$ Bn)
10.4.1. Overview
10.4.2. Hot Flashes
10.4.3. Vaginal Dryness
10.4.4. Others

11. Africa
11.1. Africa Non-Hormonal Alternatives for Menopause Market, by Country, 2016-2028(US$ Bn)
11.1.1. South Africa
11.1.2. Egypt
11.1.3. Nigeria
11.1.4. Rest of Africa
11.2. Africa Non-Hormonal Alternatives for Menopause Market, by Indication, 2016-2028(US$ Bn)
11.2.1. Overview
11.2.2. Health Women
11.2.3. Breast cancer survivors
11.3. Africa Non-Hormonal Alternatives for Menopause Market, by End-user, 2016-2028(US$ Bn)
11.3.1. Overview
11.3.2. Selective serotonin-norepinephrine reuptake inhibitors (SNRIs)
11.3.3. Plant-derived estrogens (phytoestrogens) s
11.3.4. Selective serotonin reuptake inhibitors (SSRIs)
11.3.5. Herbal treatments
11.3.6. Over-the-counter therapies
11.3.7. Others
11.4. Africa Non-Hormonal Alternatives for Menopause Market, by Therapy, 2016-2028(US$ Bn)
11.4.1. Overview
11.4.2. Hot Flashes
11.4.3. Vaginal Dryness
11.4.4. Others

12. Global
12.1. Global Non-Hormonal Alternatives for Menopause Market, by Indication, 2016-2028(US$ Bn)
12.1.1. Overview
12.1.2. Health Women
12.1.3. Breast cancer survivors
12.2. Global Non-Hormonal Alternatives for Menopause Market, by End-user, 2016-2028(US$ Bn)
12.2.1. Overview
12.2.2. Selective serotonin-norepinephrine reuptake inhibitors (SNRIs)
12.2.3. Plant-derived estrogens (phytoestrogens) s
12.2.4. Selective serotonin reuptake inhibitors (SSRIs)
12.2.5. Herbal treatments
12.2.6. Over-the-counter therapies
12.2.7. Others
12.3. Global Non-Hormonal Alternatives for Menopause Market, by Therapy, 2016-2028(US$ Bn)
12.3.1. Overview
12.3.2. Hot Flashes
12.3.3. Vaginal Dryness
12.3.4. Others

13. Company Profiles
13.1. Swor Women’s Care
13.2. Paladin Labs
13.3. Boehringer Ingelheim
13.4. Pfizer
13.5. Organon Inc.,
13.6. Lupin
13.7. GSK
13.8. Others
List of Figures

FIG. 1 Global Non-Hormonal Alternatives for Menopause Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Non-Hormonal Alternatives for Menopause Market Segmentation
FIG. 4 Global Non-Hormonal Alternatives for Menopause Market, by Indication, 2019 (US$ Bn)
FIG. 5 Global Non-Hormonal Alternatives for Menopause Market, by Hardware, 2021 (US$ Bn)
FIG. 6 Global Non-Hormonal Alternatives for Menopause Market, by End-user, 2021 (US$ Bn)
FIG. 7 Global Non-Hormonal Alternatives for Menopause Market, by Therapy, 2021 (US$ Bn)
FIG. 8 Global Non-Hormonal Alternatives for Menopause Market, by Geography, 2021 (US$ Bn)
FIG. 9 Attractive InvestHealth Woment Proposition, by Geography, 2021
FIG. 10 Global Market Positioning of Key Non-Hormonal Alternatives for Menopause Market Manufacturers, 2019
FIG. 11 Global Non-Hormonal Alternatives for Menopause Market Value Contribution, By Indication, 2021 & 2028 (Value %)
FIG. 12 Global Non-Hormonal Alternatives for Menopause Market, by Health Women, Value, 2016-2028 (US$ Bn)
FIG. 13 Global Non-Hormonal Alternatives for Menopause Market, by Breast cancer survivors, Value, 2016-2028 (US$ Bn)
FIG. 14 Global Non-Hormonal Alternatives for Menopause Market Value Contribution, By Therapy, 2021 & 2028 (Value %)
FIG. 15 Global Non-Hormonal Alternatives for Menopause Market, by Selective serotonin-norepinephrine reuptake inhibitors (SNRIs), Value, 2016-2028 (US$ Bn)
FIG. 16 Global Non-Hormonal Alternatives for Menopause Market, by Plant-derived estrogens (phytoestrogens), Value, 2016-2028 (US$ Bn)
FIG. 17 Global Non-Hormonal Alternatives for Menopause Market, by Selective serotonin reuptake inhibitors (SSRIs), Value, 2016-2028 (US$ Bn)
FIG. 18 Global Non-Hormonal Alternatives for Menopause Market, by Herbal treatments, Value, 2016-2028 (US$ Bn)
FIG. 19 Global Non-Hormonal Alternatives for Menopause Market, by Over-the-counter therapies, Value, 2016-2028 (US$ Bn)
FIG. 20 Global Non-Hormonal Alternatives for Menopause Market Value Contribution, By End-user, 2021 & 2028 (Value %)
FIG. 21 Global Non-Hormonal Alternatives for Menopause Market, by Hot Flashes, Value, 2016-2028 (US$ Bn)
FIG. 22 Global Non-Hormonal Alternatives for Menopause Market, by Vaginal Dryness, Value, 2016-2028 (US$ Bn)
FIG. 23 U.S. Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 24 Rest of North America Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 25 U.K. Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 26 Germany Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 27 France Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 28 Italy Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 29 Spain Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 30 Russia Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 31 BENELUX Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 32 Poland Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 33 Austria Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 34 Rest of Europe Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 35 Japan Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 36 China Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 37 India Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 38 South Korea Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 39 Australia Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 40 Southeast Asia Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 41 Rest of Asia Pacific Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 42 Middle East & Africa Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 43 South Africa Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 44 Nigeria Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 45 Egypt Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 46 GCC Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 47 Israel Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 48 Latin America Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 49 Mechanicalzil Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 50 Argentina Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 51 Colombia Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 52 Peru Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)
FIG. 53 Chile Non-Hormonal Alternatives for Menopause Market, 2016-2028 (US$ Bn)

List of Tables

TABLE 1 Market Snapshot: Global Beauty Devices (Non-Hormonal Alternatives for Menopause) Market
TABLE 2 Global Non-Hormonal Alternatives for Menopause Market, by Indication, 2016-2028 (US$ Bn)
TABLE 3 Global Non-Hormonal Alternatives for Menopause Market, by End-user, 2016-2028 (US$ Bn)
TABLE 4 Global Non-Hormonal Alternatives for Menopause Market, by Geography, 2016-2028 (US$ Bn)
TABLE 5 North America Non-Hormonal Alternatives for Menopause Market, by Country, 2016-2028 (US$ Bn)
TABLE 6 North America Non-Hormonal Alternatives for Menopause Market, by Indication, 2016-2028 (US$ Bn)
TABLE 7 North America Non-Hormonal Alternatives for Menopause Market, by End-user, 2016-2028 (US$ Bn)
TABLE 8 North America Non-Hormonal Alternatives for Menopause Market, by Therapy, 2016-2028 (US$ Bn)
TABLE 9 Europe Non-Hormonal Alternatives for Menopause Market, by Country, 2016-2028 (US$ Bn)
TABLE 10 Europe Non-Hormonal Alternatives for Menopause Market, by Indication, 2016-2028 (US$ Bn)
TABLE 11 Europe Non-Hormonal Alternatives for Menopause Market, by End-user, 2016-2028 (US$ Bn)
TABLE 12 Europe Non-Hormonal Alternatives for Menopause Market, by Therapy, 2016-2028 (US$ Bn)
TABLE 13 Asia Pacific Non-Hormonal Alternatives for Menopause Market, by Country, 2016-2028 (US$ Bn)
TABLE 14 Asia Pacific Non-Hormonal Alternatives for Menopause Market, by Indication, 2016-2028 (US$ Bn)
TABLE 15 Asia Pacific Non-Hormonal Alternatives for Menopause Market, by End-user, 2016-2028 (US$ Bn)
TABLE 16 Asia Pacific Non-Hormonal Alternatives for Menopause Market, by Therapy, 2016-2028 (US$ Bn)
TABLE 17 Latin America Non-Hormonal Alternatives for Menopause Market, by Country, 2016-2028 (US$ Bn)
TABLE 18 Latin America Non-Hormonal Alternatives for Menopause Market, by Indication, 2016-2028 (US$ Bn)
TABLE 19 Latin America Non-Hormonal Alternatives for Menopause Market, by End-user, 2016-2028 (US$ Bn)
TABLE 20 Latin America Non-Hormonal Alternatives for Menopause Market, by Therapy, 2016-2028 (US$ Bn)
TABLE 21 Middle East Non-Hormonal Alternatives for Menopause Market, by Country, 2016-2028 (US$ Bn)
TABLE 22 Middle East Non-Hormonal Alternatives for Menopause Market, by Indication, 2016-2028 (US$ Bn)
TABLE 23 Middle East Non-Hormonal Alternatives for Menopause Market, by End-user, 2016-2028 (US$ Bn)
TABLE 24 Middle East Non-Hormonal Alternatives for Menopause Market, by Therapy, 2016-2028 (US$ Bn)
TABLE 25 Africa Non-Hormonal Alternatives for Menopause Market, by Country, 2016-2028 (US$ Bn)
TABLE 26 Africa Non-Hormonal Alternatives for Menopause Market, by Indication, 2016-2028 (US$ Bn)
TABLE 27 Africa Non-Hormonal Alternatives for Menopause Market, by End-user, 2016-2028 (US$ Bn)
TABLE 28 Africa Non-Hormonal Alternatives for Menopause Market, by Therapy, 2016-2028 (US$ Bn)

Frequently Asked Questions:

How COVID 19 Impacted Non-Hormonal Alternatives for Menopause Market?

COVID 19 had a little impact on growth of Non-Hormonal Alternatives for Menopause market and growth declined to 7.68% in 2020 as against 14.50% in 2019

Which is the leading regional market for Non-Hormonal Alternatives for Menopause?

U.S. is the largest regional market with highest share in the total revenue generation of Non-Hormonal Alternatives for Menopause consumed in 2021

What is the major growth driving factors for global Non-Hormonal Alternatives for Menopause market?

Ever increasing health awareness and growing incidence rate of hot flashes among women reaching menopause age

Which is major segment in Non-Hormonal Alternatives for Menopause market by Indication?

Hot Flashes segment dominated the Non-Hormonal Alternatives for Menopause market in 2021 with over 40% share

Which is major segment in Non-Hormonal Alternatives for Menopause market by Therapy?

Selective serotonin reuptake inhibitors (SSRIs) segment was the largest end-user of Non-Hormonal Alternatives for Menopause in 2021 with over 20% share

United States Scalp Cooling System Market

Published:
Report ID: 36100

Japan Compression Socks Market

Published:
Report ID: 36024

Chromatography Syringes Market

Published:
Report ID: 36008

Gas Chromatography Market

Published:
Report ID: 36002

Cerebral Angiography Market

Published:
Report ID: 35929

Asia Pacific Cosmetic Surgery Market

Published:
Report ID: 35562

Drug Delivery Technologies Market

Published:
Report ID: 5510

Diabetic Footwear Market

Published:
Report ID: 4365

Cystatin C Assay Market

Published:
Report ID: 35575

Optical Microscopes Market

Published:
Report ID: 35501

Dental Biomaterials Market

Published:
Report ID: 4967

Blood Meal Market

Published:
Report ID: 35384

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN